8-K: Biofrontera's Ameluz PDT Shows Strong Phase 3 Results

Biofrontera Inc. announced positive and statistically significant top-line results from its Phase 3 clinical trial for Ameluz PDT in treating actinic keratoses on the extremities, neck, and trunk.

Summary

• The Phase 3 study of Ameluz PDT for mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk met its primary endpoint.
• Ameluz PDT demonstrated highly statistically significant superiority over vehicle gel (p<0.0003).
• Complete clearance rate in the Full Analysis Set (FAS) was 45.6% for Ameluz PDT (62/136) compared to 16.7% for vehicle PDT (6/36).
• In the Per Protocol Set (PPS), complete clearance rates were 53.2% for Ameluz PDT (58/109) versus 22.2% for vehicle PDT (6/27) (p < 0.001).
• The percentage of AK lesion clearance 12 weeks after the last PDT was 73.1% in the FAS and 80.3% in the PPS.
• Subject complete clearance rates by anatomical location were 38.5% (FAS) and 46.5% (PPS) on the extremities, and 74.1% (FAS) and 78.3% (PPS) on the neck and trunk.
• Ameluz PDT demonstrated favorable cosmetic outcomes, with investigators rating aesthetic appearance as good or very good in 75.2% of patients, and 70.9% of patients reporting similar assessments.
• High patient satisfaction was reported, with 86.3% of patients indicating they would choose PDT again for future treatment.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, as the successful Phase 3 trial significantly expands the potential market for Ameluz and strengthens Biofrontera's position in the photodynamic therapy space.

Positives

• The Phase 3 study met its primary endpoint, demonstrating highly statistically significant superiority for Ameluz PDT over vehicle gel (p<0.0003).
• Achieved a 45.6% complete clearance rate in the Full Analysis Set (FAS) and 53.2% in the Per Protocol Set (PPS), significantly higher than vehicle PDT.
• High overall AK lesion clearance rates were observed (73.1% FAS, 80.3% PPS).
• Strong clearance rates were noted on the neck and trunk (74.1% FAS, 78.3% PPS).
• Demonstrated favorable cosmetic outcomes and high patient satisfaction, with 75.2% investigator-rated good/very good aesthetic appearance and 86.3% of patients willing to choose PDT again.
• Results support the potential for label expansion beyond the face and scalp, which would significantly expand Ameluz's addressable market.

Risks

• Uncertainties inherent in the initiation and conduct of clinical trials.
• Availability and timing of data from clinical trials.
• Whether results of earlier clinical trials or trials of Ameluz in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials.
• Uncertainties associated with regulatory review of clinical trials and applications for marketing approvals.
• The impact of any extraordinary external events.
• The Company's ability to achieve and sustain profitability.
• Whether global disruptions in supply chains will impact the Company's ability to obtain and distribute its products.
• Changes in the practices of healthcare providers, including any changes to coverage, reimbursement and pricing for procedures using the Company's products.
• Whether the market opportunity for Ameluz in combination with BF-RhodoLED and/or RhodoLED XL is consistent with the Company's expectations.
• The Company's ability to retain and hire key personnel.
• The sufficiency of cash resources and need for additional financing.

Future Outlook

Biofrontera plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration in the third quarter of 2026. This submission aims to expand Ameluz's label to include the treatment of actinic keratoses on the extremities, neck, and trunk, which is expected to significantly broaden Ameluz's addressable market and clinical use.

Management Comments

• "These data support Ameluz's potential to treat broader, high-burden AK fields beyond the face and scalp, significantly expanding its potential clinical use across multiple sun-exposed body areas, underscoring the potential to expand Ameluz's addressable market beyond the face and scalp." Hermann Luebbert, CEO and Chairman of Biofrontera Inc.
• "If approved, this label expansion would provide meaningful benefit to patients with actinic keratoses on the extremities, neck, and trunk and represent an important step forward in advancing our vision to establish leadership in photodynamic therapy." Hermann Luebbert, CEO and Chairman of Biofrontera Inc.
• "Ameluz PDT is already a valuable treatment option for actinic keratoses on the face and scalp. Many patients present with lesions on other areas of the body, and these data support the potential for Ameluz PDT to expand treatment options for physicians and their patients." Nathalie Zeitouni, Professor of Dermatology at the University of Arizona College of Medicine – Phoenix and Adjunct Professor of Oncology at Roswell Park Comprehensive Cancer Center.

Industry Context

StockSavvy.ai notes that actinic keratosis is the most common skin condition diagnosed by US dermatologists, and if left untreated, it may progress to squamous cell carcinoma. The expansion of Ameluz PDT's potential treatment areas beyond the face and scalp addresses a significant unmet need for patients with lesions on other sun-exposed body parts, positioning Biofrontera to capture a larger share of this prevalent dermatological market and strengthen its leadership in photodynamic therapy.

Stakeholder Impact

• Shareholders: Positive impact due to potential market expansion and increased revenue opportunities for Ameluz.
• Patients: Significant benefit for patients with actinic keratoses on the extremities, neck, and trunk by providing an expanded and effective treatment option.
• Physicians: Expanded treatment options for dermatologists treating AKs on various sun-exposed body areas.

Next Steps

• Submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration in the third quarter of 2026.
• Patients are being followed for approximately one year after their final PDT treatment.

Key Dates

Recommendation

The highly positive Phase 3 results for Ameluz PDT, demonstrating statistically significant superiority and favorable patient outcomes, represent a critical milestone that significantly expands the drug's addressable market. The planned sNDA submission in Q3 2026, if approved, would unlock substantial revenue growth potential for Biofrontera, making the stock a strong buy for investors seeking exposure to a growing dermatology market segment.

Keywords

Biofrontera, BFRI, Ameluz, Photodynamic Therapy, PDT, Actinic Keratosis, AK, Phase 3, Clinical Trial, Dermatology, Skin Cancer, FDA, sNDA, RhodoLED, Biopharmaceutical